Abstract
Despite the use of active surgeries, radiotherapy, and chemotherapy in clinical practice, brain tumors are still a difficult health problem due to their rapid development and poor prognosis. To treat brain tumors, various nanoparticles can be used to target effective physiological conditions based on continuously changing vascular characteristics and microenvironments to promote effective brain tumor-targeting drug delivery. In addition, a brain tumor-targeting drug delivery system that increases drug accumulation in the brain tumor area and reduces toxicity in the normal brain and peripheral tissues is needed. However, the blood-brain barrier is a big obstacle for drug delivery to the brain. In this chapter, we provide a broad overview of brain drug delivery and current strategies over the last few years. In addition, several questions have been reconsidered, such as whether nanoparticles believed to be delivered to the brain can pass through the blood-brain barrier, whether the drug is delivered to the target site, and what brain tumor treatment is possible.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alfred H, Schinkel, Wagenaar Els, Deemter Liesbeth van, Mol Carla A. A. M, Borst Piet (1995) Absence of the mdr1a P-Glycoprotein in Mice affects tissue distribution and pharmacokinetics of Dexamethasone, Digoxin, and Cyclosporin A. J Clin Investig 96:1698–1699
Arcella A, Oliva MA, Staffieri S et al (2015) In vitro and in vivo effect of human lactoferrin on glioblastoma growth. J Neurosurg 123(40):1026–1035
Ballabh P, Alex B, Maiken N (2004) The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16(1):1–13
Banks WA (2016) From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 15(4):275
Barrett GC, Donald TE (1998) Amino acids and peptides. Cambridge University Press, Cambridge
Becker I (1991) The multidrug-resistance gene MDR1 is expressed in human glial tumors. Acta Neuropathol 82(6):516–519
Béduneau A, Saulnier P, Benoit JP (2007) Active targeting of brain tumors using nanocarriers. Biomaterials 28(33):4947–4967
Belotti D, Vergani V, Drudis T et al (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2(11):1843–1849
Brandes AA, Rigon A, Zampieri P et al (1996) Early chemotherapy and concurrent radio-chemotherapy in high grade glioma. J Neuro-Oncol 30(3):247–255
Bronger H, König J, Kopplow K et al (2005) ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 65(24):11419–11428
Brooks PC, Richard AC, David AC (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264(5158):569–571
Byeon HJ, Lee S, Min SY et al (2016) Doxorubicin-loaded nanoparticles consisted of cationic-and mannose-modified-albumins for dual-targeting in brain tumors. J Control Release 225:301–313
Chen Q, Wang X, Wang C et al (2015) Drug-induced self-assembly of modified albumins as nano-theranostics for tumor-targeted combination therapy. ACS Nano 9(5):5223–5233
Chu C, Abbara C, Noël-Hudson MS et al (2009) Disposition of everolimus in mdr1a−/1b− mice and after a pre-treatment of lapatinib in Swiss mice. Biochem Pharmacol 77(10):1629–1634
Dafang, Wu, Yang Jing, Pardridge William M. (1997) Drug Targeting of a Peptide Radiopharmaceutical through the Primate Blood-Brain Barrier In Vivo with a Monoclonal Antibody to the Human Insulin Receptor. J Clin Investiga 100:1804–1805
David, Mathieu, and Fortin David (2007) Chemotherapy and delivery in the treatment of primary brain tumors. Curr Clin Pharmacol 2: 197–198
DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123
Demeule M, Régina A, Jodoin J et al (2002) Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood–brain barrier. Vasc Pharmacol 38(6):339–348
Dieu LH, Wu D, Paliva CG et al (2014) Polymersomes conjugated to 83-14 monoclonal antibodies: in vitro targeting of brain capillary endothelial cells. Eur J Pharm Biopharm 88(2):316–324
Dong XW (2018) Current strategies for brain drug delivery. Theranostics 8:1481–1493
Dong H, Jin M, Liu Z et al (2016) In vitro and in vivo brain-targeting chemo-photothermal therapy using graphene oxide conjugated with transferrin for gliomas. Lasers Med Sci 31(6):1123–1131
Dorothy T. Krieger, author (1983) Brain peptides: what, where, and why?. Science 222:975–985
Dube B, Pandey A, Joshi G et al (2017) Hydrophobically modified polyethylenimine-based ternary complexes for targeting brain tumor: stability, in vitro and in vivo studies. Artif Cells Nanomed Biotechnol 45(8):1685–1698
Elzoghby AO, Samy WM, Elgindy NA (2012) Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157(2):168–182
Elzoghby AO, Helmy MW, Samy WM (2013a) Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model. Pharm Res 30(10):2654–2663
Elzoghby AO, Saad NI, Helmy MW et al (2013b) Ionically-crosslinked milk protein nanoparticles as flutamide carriers for effective anticancer activity in prostate cancer-bearing rats. Eur J Pharm Biopharm 85(3):444–451
Elzoghby AO, Samy WM, Elgindy NA (2015) Swellable floating tablet based on spray-dried casein nanoparticles: near-infrared spectral characterization and floating matrix evaluation. Int J Pharm 491(1–2):113–122
Elzoghby AO, Abd-Elwakil MM, Abd-Elsalam K et al (2016a) Natural polymeric nanoparticles for brain-targeting: implications on drug and gene delivery. Curr Pharm Des 22(22):3305–3323
Elzoghby AO, Hemasa AL, Freag MS (2016b) Hybrid protein-inorganic nanoparticles: from tumor-targeted drug delivery to cancer imaging. J Control Release 243:303–322
Faith G, Davis, and McCarthy Bridget J. (2001) Current epidemiological trends and surveillance issues in brain tumors’, Expert Review of Anticancer Therapy 1:395–396
Fang JH, Chiu TL, Huang WC et al (2016) Dual-targeting lactoferrin-conjugated polymerized magnetic polydiacetylene-assembled nanocarriers with self-responsive fluorescence/magnetic resonance imaging for in vivo brain tumor therapy. Adv Healthc Mater 5(6):688–695
Fattori S, Becherini F, Cianfriglia M et al (2007) Human brain tumors: multidrug-resistance p-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Virchows Arch 451(1):81–87
Fondell A, Edwards K, Ickenstein LM et al (2010) Nuclisome: a novel concept for radionuclide therapy using targeting liposomes. Eur J Nucl Med Mol Imaging 37(1):114–123
Friedman HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6(7):2585–2597
Gallo JM, Li S, Guo P et al (2003) The effect of p-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 63(16):5114–5117
Gao H (2016) Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 6(4):268–286
Gao K, Jiang X (2006) Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm 310(1–2):213–219
Gao H, Pang Z, Jiang X (2013) Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res 30(10):2485–2498
Goyal D, Shuaid S, Mann S et al (2017) Rationally designed peptides and peptidomimetics as inhibitors of amyloid-β (Aβ) aggregation: potential therapeutics of Alzheimer’s disease. ACS Comb Sci 19(2):55–80
Grant DS, Williams TL, Zahaczewsky M et al (2003) Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104(1):121–129
Groothuis DR (2000) The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-Oncology 2(1):45–59
Guerra M, Blázquez JL, Rodríguez EM (2017) Blood–brain barrier and foetal-onset hydrocephalus, with a view on potential novel treatments beyond managing CSF flow. Fluids Barriers CNS 14(1):19
Guo L, Ren J, Jiang X (2012) Perspectives on brain-targeting drug delivery systems. Curr Pharm Biotechnol 13(12):2310–2318
Hajek R, Vorlicek J, Slavik M (1996) Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. Neoplasma 43(3):141–154
Helgason HH, Kruijtzer CM, Huitema AD et al (2006) Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. Br J Cancer 95(7):794–800
Hiroko, Ohgaki, and Kleihues Paul (2005) Epidemiology and etiology of gliomas. Acta Neuropathologica 109: 93–94
Hobbs SK, Monsky WL, Rk J et al (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Nati Acad Sci 95(8):4607–4612
Hu K, Shi Y, Jiang W et al (2011) Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson’s disease. Int J Pharm 4150(1–2):273–283
Huang S, Shao K, Kuang Y et al (2013) Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 7(3):2860–2871
Huo H, Gao Y, Wang Y et al (2015) Polyion complex micelles composed of pegylated polyasparthydrazide derivatives for siRNA delivery to the brain. J Colloid Interface Sci 447:8–15
Huynh E, Zheng G (2015) Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Nanomedicine 10(13):1993–1995
Huynh GH, Deen DF, Szoka FC Jr (2006) Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release 110(2):236–259
Iinuma H, Maruyama K, Okinaga K et al (2002) Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 99(1):130–137
Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47(12):3039–3051
Jiang L, Jiang S, Zhang M et al (2014) Albumin versus other fluids for fluid resuscitation in patients with sepsis: a meta-analysis. PLoS One 9(12):1–21
Jose S, Sowmya S, Cinu TA et al (2014) Surface modified PLGA nanoparticles for brain targeting of bacoside-a. Eur J Pharm Sci 63:29–35
Joseph A (2007) Overview of the changing paradigm in cancer treatment: Oral chemotherapy. American J Health-System Pharm 64: S4-NaN
Juillerat Jeanneret L (2008) The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13(23–24):1099–1106
Karami Z, Saghatchi Zanjani MR, Rezaee S et al (2019) Neuropharmacokinetic evaluation of lactoferrin-treated indinavir-loaded nanoemulsions: remarkable brain delivery enhancement. Drug Dev Ind Pharm 45(5):736–744
Karim R, Palazzo C, Evrard B et al (2016) Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Control Release 227:23–37
Karimi M, Bahrami S, Ravari SB et al (2016) Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv 13(11):1609–1623
Kemper EM, van Zandbergen AE, Cleypool C et al (2003) Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res 9(7):2849–2855
Kim S, Bell K, Mousa SA et al (2000) Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am J Pathol 156(4):1345–1362
Komarova YA, Kruse K, Mehta D et al (2017) Protein interactions at endothelial junctions and signaling mechanisms regulating endothelial permeability. Circ Res 120(1):179–206
Kuang Y, An S, Guo Y et al (2013) T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int J Pharm 454(1):11–20
Kumar CC, Armstrong L, Yin Z et al (2000) Targeting integrins α v β 3 and α v β 5 for bloking tumor-induced angiogenesis. Adv Exp Med Biol 476:169–180
Kunal S, Taskar, Rudraraju Vinay, Mittapalli Rajendar K, Samala Ramakrishna, Thorsheim Helen R, Lockman Julie, Gril Brunilde, Hua Emily, Palmieri Diane, Polli Joseph W, Castellino Stephen, Rubin Stephen D, Lockman Paul R, Steeg Patricia S, and Smith Quentin R. (2012) Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. Pharmaceutical Res 29: 770–771
Kuo YC, Chen YC (2015) Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin-and folic acid-grafted poly (lactide-co-glycolide) nanoparticles. Int J Pharma 479(1):138–149
Lécuyer MA, Saint Laurent O, Larouche S et al (2017) Dual role of ALCAM in neuroinflammation and blood–brain barrier homeostasis. Proc Nati Acad Sci U S A 114(4):E524–E533
Lee JH, Engler JA, Collawn JF et al (2001) Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem 268(7):2004–2012
Li Y, He H, Jia X et al (2012) A dual-targeting nanocarrier based on poly (amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 33(15):3899–3908
Li S, Amat D, Peng Z et al (2016) Transferrin conjugated nontoxic carbon dots for doxorubicin delivery to target pediatric brain tumor cells. Nanoscale 8(37):16662–16669
Lin T, Zhao P, Jiang Y et al (2016) Blood–brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano 10(11):9999–10012
Liu Y, Lu W (2012) Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin Drug Deliv 9(6):671–686
Liu Y, An S, Li J et al (2016) Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer’s disease mice. Biomaterials 80:33–45
Liu C, Liu XN, Wang GL et al (2017) A dual-mediated liposomal drug delivery system targeting the brain: rational construction, integrity evaluation across the blood–brain barrier, and the transporting mechanism to glioma cells. Int J Nanomedicine 12:2407
Lu W, Zhaog Y, Tan YZ et al (2005) Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 107(3):428–448
Luo B, Wang S, Rao R et al (2016) Conjugation magnetic PAEEP-PLLA nanoparticles with lactoferrin as a specific targeting MRI contrast agent for detection of brain glioma in rats. Nanoscale Res Lett 11(1):227
Mäger I, Meyer AH, Li J et al (2017) Targeting blood-brain-barrier transcytosis–perspectives for drug delivery. Neuropharmacology 120:4–7
Martin C, Berridge G, Higgins CF et al (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharm 58(3):624–632
Martins SM, Sarmento B, Nunes C et al (2013) Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharma Biopharm 85(3):488–502
Masanao, Mohri, Nitta Hisashi, and Yamashita Junkoh (2000) Expression of multidrug resistance-associated protein (MRP) in human gliomas. J Neuro-Oncol 49:105–106
Miao D, Jiang M, Liu Z et al (2013) Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy. Mol Pharm 11(1):90–101
Monsky WL, Mouta Carreira C, Tsuzuki Y et al (2002) Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 8(4):1008–1013
Newton HB (1994) Primary brain tumors: review of etiology, diagnosis and treatment. Am Fam Physician 49(4):787–797
Ningaraj NS, Rao M, Hashizume K et al (2002) Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharm Exp Ther 301(3):838–851
Oberoi RK, Parrish KE, Sio TT et al (2015) Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma. Neuro-oncol 18(1):27–36
Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170(5):1445–1453
Omuro AMP, Faivre S, Raymond E (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6(7):1909–1919
Paek IB, Ji HY, Kim MS et al (2006a) Metabolism of a new p-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/electrospray mass spectrometry. Rapid Commun Mass Spectrom 20(9):1457–1462
Paek IB, Ji HY, Kim MS et al (2006b) Simultaneous determination of paclitaxel and a new p-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry. J Sep Sci 29(5):628–634
Pang Z, Lu K, Gao H et al (2008) Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 128(2):120–127
Pang Z, Feng L, Hua R et al (2010) Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm 7(6):1995–2005
Pang Z, Gao H, Guo L et al (2011a) Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin. Bioconjug Chem 22(6):1171–1180
Pang Z, Gao H, Yu Y et al (2011b) Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes. Int J Pharm 415(1–2):284–292
Pardridge WM (1991) Peptide drug delivery to the brain. Raven Press, New York
Park TE, Singh B, Li H et al (2015) Enhanced BBB permeability of osmotically active poly (mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer’s disease. Biomaterials 38:61–71
Pasquier E, Pourroy B, Camoin L et al (2004) Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 3(10):1301–1310
Pehlivan SB (2013) Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm Res 30(10):2499–2511
Polli JW, Olson KL, Chism JP et al (2009) An unexpected synergist role of p-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl) oxy] phenyl}-6-[5-({[2-(methylsulfonyl) ethyl] amino} methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37(2):439–442
Provenzale JM, Mukundan S, Dewhirst M (2005) The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. AJR Am J Roentgenol 185(3):763–767
Qian ZM, Li H, Sun H et al (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54(4):561–587
Re F, Cambianica I, Zona C et al (2011) Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine 7(5):551–559
Roberts WG, Delaat J, Nagane M et al (1998) Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol 153(4):1239–1248
Rousselle C, Clair P, Temsamani J et al (2000) New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 57(4):679–686
Salphati L, Lee LB, Pang J et al (2010) Role of p-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 38(9):1422–1426
Salphati L, Pang J, Plise EG et al (2012) Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metab Dispos 40(9):1785–1796
Salzano G, Zappavigna S, Luce A et al (2016) Transferrin-targeted nanoparticles containing zoledronic acid as a potential tool to inhibit glioblastoma growth. J Biomed Nanotechnol 12(4):811–830
Sarin H, Wu H, Hall MD et al (2008) Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Ttransl Med 6(1):80
Sarin H, Wu H, Vo HQ et al (2009) Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med 7(1):51
Schinkel AH, Smit JJ, te Riele HP et al (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77(4):491–502
Schlageter KE, Molnar P, Lapin GD et al (1999) Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 58(3):312–328
Shai RM, Reichatdt JK, Chen TC (2008) Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. Future Oncol 4:525–534
Sobin LH (1981) The international histological classification of tumours. Bull World Health Organ 59(6):813–819
Song XL, Xiao Y, Cheng L et al (2017) Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer. Int J Nanomedicine 12:7433–7451
Spano JP, Fagard R, Soria JC et al (2005) Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 16(2):189–194
Sparreboom A, Van Asperen J, Mayer U et al (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. PNAS 94(5):2031–2035
Stephan, Fellner, Bauer Björn, Miller David S, Schaffrik Martina, Fankhänel Martina, Spru Thilo, Bernhardt Günther, Graeff Claudia, Färber Lothar, Gschaidmeier Harald, Buschauer Armin, and Fricker Gert. 2002. ‘Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Investig 110: 1309–1310
Su Z, Xing L, Chen Y et al (2014) Lactoferrin-modified poly (ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas. Mol Pharm 11(6):1823–1834
Takasato Y, Rapoport SI, Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Phys 247(3):H484–H493
Tamaru M, Akita H, Harashima H et al (2014) Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain. Int J Nanomedicine 9:4267–4276
Tong H, Wang Y, Lu X et al (2015) On the preparation of transferrin modified artesunate nanoliposomes and their glioma-targeting treatment in-vitro and in-vivo. Int J Clin Exp Med 8(12):22045–22052
Tsutsui Y, Tomizawa K, Nagita M et al (2007) Development of bionanocapsules targeting brain tumors. J Control Release 122(2):159–164
Van Asperen J, Schinkel AH, van Tellingen O et al (1996) Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. J Nati Cancer Inst 88(14):994–999
Van Asperen J, Borst P, Beijnen JH et al (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76(9):1181–1183
Vlieghe P, Khrestxgatisky M (2012) Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med Res Rev 33(3):457–516
Wang X, Tu M, Tian B et al (2016) Synthesis of tumor-targeted folate conjugated fluorescent magnetic albumin nanoparticles for enhanced intracellular dual-modal imaging into human brain tumor cells. Anal Biochem 512:8–17
Wei X, Chen X, Ying M et al (2014) Brain tumor-targeted drug delivery strategies. Acta Pharm Sin B 4(3):193–201
Wilson B, Lavanya Y, Jenita JL et al (2014) Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. Int J Pharm 473(1–2):73–79
Xin-Hua, Tian, Lin Xiao-Ning, Wei Feng et al (2011) Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomed 2011:445–452
Yano S, Kondo K, Wadsworth P et al (2003) Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23(5A):3639–3650
Zensi A, Begley D, Kreuter J et al (2010) Human serum albumin nanoparticles modified with apolipoprotein AI cross the blood-brain barrier and enter the rodent brain. J Drug Target 18(10):842–848
Zhan C, Lu W (2012) The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery. Curr Pharma Biotechnol 13(12):2380–2387
Zhan C, Gu B, Lu W et al (2010) Cyclic RGD conjugated poly (ethylene glycol)-co-poly (lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release 143(1):136–142
Zhan C, Li B, Lu W et al (2011) Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand. Angew Chem Int Ed Engl 50(24):5482–5485
Zhan C, Meng Q, Lu W et al (2012) Cyclic RGD–polyethylene glycol–Polyethylenimine for intracranial glioblastoma-targeted gene delivery. Chem Asian J 7(1):91–96
Zhang TT, Li W, Liao W et al (2016) Strategies for transporting nanoparticles across the blood–brain barrier. Biomater Sci 4(2):219–229
Zhou Q, Mu K, Yang X et al (2015) Glioma-targeting micelles for optical/magnetic resonance dual-mode imaging. Int J Nanomedicine 10:1805–1818
Acknowledgements
This study was supported by the Bio & Medical Technology Development Program (NRF-2015M3A9E2030125) and was partially supported by the Creative Materials Discovery Program (NRF-2017M3D1A1039289) through the National Research Foundation (NRF) funded by the Korean government (MSIP & MOHW). Also, this study was partially supported by a grant of the Korea Health Technology R&D project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0453).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Hwang, H.H., Lee, D.Y. (2020). Protein-Based Drug Delivery in Brain Tumor Therapy. In: Chun, H.J., Reis, R.L., Motta, A., Khang, G. (eds) Bioinspired Biomaterials. Advances in Experimental Medicine and Biology, vol 1249 . Springer, Singapore. https://doi.org/10.1007/978-981-15-3258-0_13
Download citation
DOI: https://doi.org/10.1007/978-981-15-3258-0_13
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-3257-3
Online ISBN: 978-981-15-3258-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)